查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772409

外用药物 CDMO 市场规模、份额和趋势分析报告：按剂型、服务、最终用途、地区和细分市场预测，2025 年至 2033 年

Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Formulation (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products), By Service, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

外用药物 CDMO 市场成长与趋势：

根据Grand View Research, Inc.的最新报告，全球局部药物CDMO市场规模预计到2033年将达到142.2亿美元，2025年至2033年期间的复合年增长率为7.5%。

针对各种皮肤相关疾病和皮肤病的专用外用药物需求日益增长。医疗保健提供者和患者正在寻求客製化解决方案，这导致对拥有外用药物专业知识的CDMO的需求日益增长。

市场碎片化，多家公司拥有相似的技术力和加工能力。乳化、奈米技术和经皮吸收贴片等创新药物传递技术的发展，提升了CDMO开发更利于病患、更有效的外用药物的能力。此外，个人化医疗的日益普及也显着提升了对外用CDMO的需求，因为它们在根据患者个别情况和需求提供个人化外用药物治疗方面发挥着重要作用。

CDMO与製药公司之间的合作日益增多，CDMO为创新型外用药物的生产和开发做出了贡献。製药公司通常选择将生产服务委託给专业的CDMO，同时专注于自身的核心竞争力，例如研发、分销和行销。 FDA核准的外用药物数量和产品上市数量的不断增加，是专门从事外用药物生产的CDMO数量增长的主要推动力。例如，2022年5月，Dermavant Sciences公司获得美国食品药物管理局(FDA)核准，其1% VTAMA（tapinarof）乳膏可用于治疗成人斑块型干癣的局部治疗。

新冠疫情对市场产生了负面影响。疫情严重扰乱了全球供应链，影响了生产能力和原料供应。由于安全问题，包括外用药物在内的多项临床试验被暂时推迟或搁置。这阻碍了新型外用药物和製剂的测试和开发。然而，透过采取收购和与专业製药商合作等策略性倡议，该产业在2021年恢復了市场占有率。

外用药物CDMO市场报告重点

  • 以剂型划分，半固态剂型市场在2024年的收入份额最高，为66.44%。该市场的成长动力源于乳膏、凝胶和软膏需求的不断增长，以及外用药物临床试验的增加。同时，由于针对多种疾病的外用乳膏核准不断增加，因此乳膏子类别预计将占据相当大的份额。
  • 按服务划分，契约製造部门在 2024 年占据了最大的收入份额。该部门份额高是由于对製造外包服务的需求不断增加，这主要受到製造外包的成本效益的推动。
  • 根据最终用途，由于与外用药物开发相关的研发活动的增加，该生物製药公司预计将在预测期内实现最高的复合年增长率。
  • 预计亚太地区在预测期内将实现显着的复合年增长率。该地区的显着成长可归因于外用产品生产成本的提高，这主要得益于多个亚洲经济体较低的人事费用和营运成本。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章 外用药物 CDMO 市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 技术格局
  • 定价模式分析
  • 研发成本分析（2021-2024）
  • 市场分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析

第四章 外用药物 CDMO 市场：以剂型进行的估算与趋势分析

  • 外用药物 CDMO 市场（按剂型）：细分仪表板
  • 外用药物 CDMO 市场（按剂型）：差异分析
  • 按剂型划分，2021-2033年
  • 半固态製剂
    • 奶油
    • 软膏
    • 凝胶
    • 其他的
  • 液体製剂
  • 固态製剂
  • 经皮产品

第五章 外用药物 CDMO 市场：依服务与趋势分析估算

  • 外用药物 CDMO 市场、服务细分仪表板
  • 外用药物CDMO市场（按服务）：变化分析
  • 按服务划分，2021-2033 年
  • 合约开发
  • 契约製造

第六章 局部用药 CDMO 市场：最终用途估算与趋势分析

  • 外用药物 CDMO 市场（依最终用途）：细分仪表板
  • 外用药物 CDMO 市场（依最终用途划分）：差异分析
  • 依最终用途，2021-2033 年
  • 製药公司
  • 生物製药公司
  • 其他的

第七章：外用药物 CDMO 市场：区域估计与趋势分析

  • 区域市场仪表板
  • 2024 年及 2033 年区域市场占有率分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与企业
  • 2024年市场分析（热图分析）
  • 公司简介
    • Lubrizol Life Science
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • MedPharm Ltd
    • PCI Pharma Services

第九章 主要建议

Product Code: GVR-4-68040-150-0

Topical Drugs CDMO Market Growth & Trends:

The global topical drugs CDMO market size is expected to reach USD 14.22 billion by 2033, registering a CAGR of 7.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. There is an increasing need for specialized topical drugs to address various skin-related and dermatological conditions. Healthcare providers and patients seek customized solutions, leading to a rise in demand for CDMOs with specialized expertise in topical drugs.

The market is fragmented, with several players having similar technological and processing capabilities. The development of innovative drug delivery technologies, such as microemulsions, nanotechnology, and transdermal patches, has extended the abilities of CDMOs to create more patient-friendly and effective topical drug products. Furthermore, a growing trend towards personalized medicine has significantly boosted demand for topical drug CDMOs, as they play a fundamental role in personalizing topical treatments to individual patient conditions and needs.

Collaborations between CDMOs and pharmaceutical companies have risen, with CDMOs contributing to the manufacturing and development of innovative and new topical drugs. Pharmaceutical firms significantly opt for outsourcing with an aim to focus on core competencies such as research, distribution, and marketing while entrusting manufacturing services to dedicated CDMOs. The increasing number of FDA approvals and product launches in topical medications significantly contributes to CDMOs specializing in topical drug manufacturing growth. For instance, in May 2022, Dermavant Sciences received the U.S. Food and Drug Administration (FDA) approval for its VTAMA (tapinarof) cream, 1%, for the topical management of plaque psoriasis in adults.

The COVID-19 pandemic negatively impacted the market. The pandemic has significantly disrupted the global supply chains, affecting the accessibility of manufacturing capabilities and raw materials. Several clinical studies, including those for topical medicine, were temporarily delayed or put on hold owing to safety concerns. This disturbed the testing and development of new topical drug treatments and formulations. However, by adopting strategic initiatives such as acquisition and partnerships with specialized drug providers, the industry regained its market shares by 2021.

Topical Drugs CDMO Market Report Highlights:

  • Based on formulation, the semi-solid formulations segment held the largest revenue share of 66.44% in 2024.The segment is driven by the growing demand for creams, gels, and ointments and the rise in clinical trials involving topical drugs. The cream sub-category, on the other hand, held the lion's share owing to increasing approval of topical creams for several medical conditions.
  • Based on the service, the contract manufacturing segment held the largest revenue share in 2024. The high shares of the segment are majorly due to the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
  • In terms of end-use, the biopharmaceutical companies segment is anticipated to witness highest CAGR during the forecast period owing to the rise in focus on R&D activities pertaining to the development of topical medication.
  • Asia Pacific is anticipated to register the significant CAGR over the forecast period. The region's substantial growth is primarily attributed to the cost-effective manufacturing of topical products due to lower labor and operational costs in several Asian economies.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Formulation
    • 1.2.2. Service
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High demand for non-invasive treatment options to boost sales of topical drugs
      • 3.2.1.2. Growing pipeline of topical drugs
      • 3.2.1.3. Growing research and development investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. R&D Spending Analysis (2021-2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Topical Drugs CDMO Market: Formulation Estimates & Trend Analysis

  • 4.1. Topical Drugs CDMO Market, By Formulation: Segment Dashboard
  • 4.2. Topical Drugs CDMO Market, By Formulation: Movement Analysis
  • 4.3. Topical Drugs CDMO Market Estimates & Forecasts, By Formulation, 2021 - 2033 (USD Million)
  • 4.4. Semi-solid Formulations
    • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Creams
      • 4.4.2.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Ointments
      • 4.4.3.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Gel
      • 4.4.4.1. Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Liquid Formulations
    • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Solid Formulations
    • 4.6.1. Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transdermal Products
    • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Topical Drugs CDMO Market, Service: Segment Dashboard
  • 5.2. Topical Drugs CDMO Market, Service: Movement Analysis
  • 5.3. Topical Drugs CDMO Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Contract Development
    • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Topical Drugs CDMO Market, By End Use: Segment Dashboard
  • 6.2. Topical Drugs CDMO Market, By End Use: Movement Analysis
  • 6.3. Topical Drugs CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biopharmaceutical Companies
    • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Topical Drugs CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Lubrizol Life Science
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Pierre Fabre group
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. DPT Laboratories, LTD
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. MedPharm Ltd
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. PCI Pharma Services
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

Chapter 9 Key Recommendations

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 5 Global Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 Global Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 Global Topical Drugs CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 10 North America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 11 North America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 13 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 15 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 17 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 Canada Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 20 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 23 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 24 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 25 Europe Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 27 UK Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 28 UK Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 30 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 31 Germany Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 32 France Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 33 France Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 34 France Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 36 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 37 Italy Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 39 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 40 Spain Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 42 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 43 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 44 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 45 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 46 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 47 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 48 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 49 Norway Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 54 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 55 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 56 Japan Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 China Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 58 China Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 59 China Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 60 India Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 61 India Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 62 India Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 63 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 64 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 65 Australia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 67 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 68 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 69 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 70 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 73 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 74 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 75 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 76 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 77 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 79 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 81 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 84 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 85 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 87 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 88 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 91 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 92 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 93 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 94 UAE Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 97 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Topical Drugs CDMO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Topical Drugs CDMO Market: Formulation outlook and key takeaways
  • Fig. 20 Topical Drugs CDMO Market: Formulation movement analysis
  • Fig. 21 Semi-solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Topical Drugs CDMO Market: Service outlook and key takeaways
  • Fig. 30 Topical Drugs CDMO Market: Service movement analysis
  • Fig. 31 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Topical Drugs CDMO Market: End Use outlook and key takeaways
  • Fig. 34 Topical Drugs CDMO Market: End Use movement analysis
  • Fig. 35 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 North America Topical Drugs CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 South Korea Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 UAE Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key company categorization
  • Fig. 91 Service heat map analysis
  • Fig. 92 Strategic framework